SAN DIEGO—Jake Leach has officially taken over as the new president and CEO of DexCom, Inc., a glucose biosensing corporation. Leach assumed his expanded responsibilities on Jan. 1.
“I’ve had the honor of playing a role in shaping Dexcom’s industry-defining innovation since joining the company more than 20 years ago," said Leach. "From building the technology as an engineer in my early days, to advancing global scale to meet our long-term growth demand as COO, it’s an honor to step into the role of CEO during such a pivotal moment for the business—and a growing global metabolic health crisis. I look forward to further advancing Dexcom’s long legacy of empowering people to take control of health.”
Leach's first public engagement as CEO was at CES 2026 on Jan. 7, where he was joined on a mainstage panel alongside leaders from Dexcom partners ŌURA and Rimidi examining the revolutionary impact of continuous health monitoring for users, clinicians and the health care system at large.
Leach assumes the role of CEO from Kevin Sayer, who spent the last decade guiding Dexcom through unprecedented growth. Under Sayer’s leadership, Dexcom said it grew from approximately $250 million to more than $4.6 billion in annual revenue and pioneered the CGM category with a long list of industry firsts, including the first approval to replace fingersticks in treatment decisions, the first approval to send glucose data directly to smartphones and the first CGM cleared for use in the United States without a prescription, among other accomplishments.